{"id":943135,"date":"2026-03-10T09:12:24","date_gmt":"2026-03-10T13:12:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\/"},"modified":"2026-03-10T09:12:24","modified_gmt":"2026-03-10T13:12:24","slug":"bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\/","title":{"rendered":"bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath\u00ae Lung Cancer Diagnostic"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath\u00ae Lung Cancer Diagnostic<\/b><\/p>\n<p class=\"bwalignc\"><b><i>Study to evaluate clinical performance of CyPath\u00ae Lung for the early detection of lung cancer in high-risk patients<\/i><\/b><\/p>\n<p class=\"bwalignc\"><b><i>Murtha Cancer Center Research Program at Uniformed Services University of the Health Sciences provides support for longitudinal study<\/i><\/b><\/p>\n<p>SAN ANTONIO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bioaffinitytech.com&amp;esheet=54442785&amp;newsitemid=20260310050054&amp;lan=en-US&amp;anchor=bioAffinity+Technologies%2C+Inc.&amp;index=1&amp;md5=306aa0bb1872074d4cd2c483a078bdcd\"><b>bioAffinity Technologies, Inc.<\/b><\/a><b> (Nasdaq: BIAF; BIAFW)<\/b>,<b \/>a biotechnology company focused on non-invasive diagnostics and early cancer detection, today announced initiation of the Company\u2019s planned large-scale, longitudinal clinical study for CyPath\u00ae Lung, its noninvasive diagnostic test for the detection of early-stage lung cancer.<\/p>\n<p>\nThe 2,000-patient longitudinal study is designed to evaluate the clinical performance of the CyPath\u00ae Lung flow cytometry test as a noninvasive diagnostic that uses sputum samples to detect the presence of lung cancer in high-risk individuals with existing lung nodules six millimeters (mm) to less than 30 mm in diameter identified by lung cancer screening. In an earlier clinical trial, CyPath\u00ae Lung showed 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients with small pulmonary nodules less than 20mm. Several recent patient case studies demonstrate the test\u2019s ability to detect lung cancer at its curative Stage 1A.<\/p>\n<p>\nbioAffinity Technologies expects up to 20 clinical study sites, including a dozen Department of Veterans Affairs (VA) medical centers and two of the nation\u2019s largest military hospitals, will participate in the study. Michael J. Morris, MD, pulmonology and critical care physician at Brooke Army Medical Center, is the national Principal Investigator for the study (NCT07168993). The John P. Murtha Cancer Center Research Program (MCCRP), a research program within the Department of Surgery at the Uniformed Services University of the Health Sciences in Bethesda, Maryland, is providing support and funding associated with the trial at several federal facilities.<\/p>\n<p>\nPhysicians currently order CyPath\u00ae Lung, a laboratory developed test (LDT) offered by bioAffinity Technologies\u2019 subsidiary Precision Pathology Laboratory Services, for their patients with indeterminate lung nodules to determine next steps in patient care.<\/p>\n<p>\nThe longitudinal clinical trial announced today will evaluate FlowPath Lung, a research-use test that uses the same technology and follows the same procedures as CyPath\u00ae Lung. The different name is simply used to distinguish the investigational assay from the commercially available test.<\/p>\n<p>\n\u201cAs more indeterminate pulmonary nodules are found either incidentally or by routine lung cancer screening, CyPath\u00ae Lung can fill the diagnostic gap between \u2018watchful waiting\u2019 and invasive procedures that carry risk,\u201d said Gordon Downie, MD, PhD, Chief Medical Officer of bioAffinity Technologies. \u201cAs a result, we see growing adoption and use of CyPath\u00ae Lung by physicians and expect this longitudinal trial to provide additional evidence to support inclusion of our noninvasive test as part of the standard of care for lung cancer screening and diagnosis.\u201d<\/p>\n<p>\n\u201cInitiating this study represents an important milestone for CyPath\u00ae Lung,\u201d said Maria Zannes, President and CEO of bioAffinity Technologies. \u201cBy following patients longitudinally across multiple sites, we expect to acquire robust, real-world data that reflects how CyPath\u00ae Lung may be used to support risk assessment and clinical decision-making aligned with our objective to establish CyPath\u00ae Lung as a standard of care for evaluating patients at high-risk for early-stage lung cancer.\u201d<\/p>\n<p>\nThe study includes participation from several federal facilities to examine the test&#8217;s performance in diverse patient populations, including military service members and veterans. Patient enrollment is expected to take up to 18 months with patients followed for up to 24 months or until a definitive diagnosis of cancer or no cancer is determined.<\/p>\n<p><b>About CyPath\u00ae Lung<\/b><\/p>\n<p>\nCyPath\u00ae Lung is a non-invasive test designed to improve the early detection of lung cancer in patients at high risk for the disease. CyPath\u00ae Lung uses advanced flow cytometry and proprietary artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. CyPath\u00ae Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Frespiratory-research.biomedcentral.com%2Farticles%2F10.1186%2Fs12931-023-02327-3&amp;esheet=54442785&amp;newsitemid=20260310050054&amp;lan=en-US&amp;anchor=Clinical+study+results&amp;index=2&amp;md5=52cc64581b6625e50df4113be9c0f4c8\">Clinical study results<\/a> demonstrated 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small indeterminate lung nodules less than 20 millimeters.<\/p>\n<p><b>About bioAffinity Technologies, Inc.<\/b><\/p>\n<p>\nbioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company\u2019s first product, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cypathlung.com%2F&amp;esheet=54442785&amp;newsitemid=20260310050054&amp;lan=en-US&amp;anchor=CyPath%26%23174%3B+Lung&amp;index=3&amp;md5=81a7375a091a783a145f24a829084179\">CyPath\u00ae Lung<\/a>, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath\u00ae Lung is marketed as a Laboratory Developed Test (LDT) by <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.precisionpath.us%2F&amp;esheet=54442785&amp;newsitemid=20260310050054&amp;lan=en-US&amp;anchor=Precision+Pathology+Laboratory+Services&amp;index=4&amp;md5=4fc94ca97a64af374b76fcdb137cb909\">Precision Pathology Laboratory Services<\/a>, a subsidiary of bioAffinity Technologies. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fbioaffinitytech.com%2F&amp;esheet=54442785&amp;newsitemid=20260310050054&amp;lan=en-US&amp;anchor=www.bioaffinitytech.com&amp;index=5&amp;md5=048f1016fc345609e7cbffff1e8e0c90\">www.bioaffinitytech.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nCertain statements in this press release constitute &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws. Words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;predict,&#8221; &#8220;forecast,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;intend&#8221; or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of CyPath\u00ae Lung to identify lung cancer in difficult-to-diagnose patients; the benefits of adding CyPath\u00ae Lung to the standard of care for evaluating indeterminate lung nodules; CyPath\u00ae Lung providing clarity when imaging and risk models are inconclusive; the ability to initiate and conduct the study as planned; challenges in patient identification, enrollment, retention, and protocol adherence; site performance and operational execution; variability in study data and outcomes; the possibility that study results do not demonstrate the anticipated performance or clinical utility; changes in standards of care, competitive developments, or technological advances; delays or difficulties in obtaining, maintaining, or expanding regulatory approvals or clearances; manufacturing, quality, supply chain, and scaling challenges; reimbursement and coverage uncertainties; the ability to obtain clinician and patient adoption; and the other factors discussed in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260310050054r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260310050054\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260310050054\/en\/<\/a><\/span><\/p>\n<p>\nbioAffinity Technologies<br \/>\n<br \/>Julie Anne Overton<br \/>\n<br \/>Director of Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@bioaffinitytech.com\">investors@bioaffinitytech.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Texas United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Technology Clinical Trials Software Biotechnology Pharmaceutical Health Science Oncology Artificial Intelligence<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260310050054\/en\/797432\/3\/bioAfinity_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath\u00ae Lung Cancer Diagnostic Study to evaluate clinical performance of CyPath\u00ae Lung for the early detection of lung cancer in high-risk patients Murtha Cancer Center Research Program at Uniformed Services University of the Health Sciences provides support for longitudinal study SAN ANTONIO&#8211;(BUSINESS WIRE)&#8211;bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company focused on non-invasive diagnostics and early cancer detection, today announced initiation of the Company\u2019s planned large-scale, longitudinal clinical study for CyPath\u00ae Lung, its noninvasive diagnostic test for the detection of early-stage lung cancer. The 2,000-patient longitudinal study is designed to evaluate the clinical performance of the CyPath\u00ae Lung flow cytometry test as a noninvasive diagnostic that uses sputum &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath\u00ae Lung Cancer Diagnostic&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-943135","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath\u00ae Lung Cancer Diagnostic - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath\u00ae Lung Cancer Diagnostic - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath\u00ae Lung Cancer Diagnostic Study to evaluate clinical performance of CyPath\u00ae Lung for the early detection of lung cancer in high-risk patients Murtha Cancer Center Research Program at Uniformed Services University of the Health Sciences provides support for longitudinal study SAN ANTONIO&#8211;(BUSINESS WIRE)&#8211;bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company focused on non-invasive diagnostics and early cancer detection, today announced initiation of the Company\u2019s planned large-scale, longitudinal clinical study for CyPath\u00ae Lung, its noninvasive diagnostic test for the detection of early-stage lung cancer. The 2,000-patient longitudinal study is designed to evaluate the clinical performance of the CyPath\u00ae Lung flow cytometry test as a noninvasive diagnostic that uses sputum &hellip; Continue reading &quot;bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath\u00ae Lung Cancer Diagnostic&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-10T13:12:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260310050054r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath\u00ae Lung Cancer Diagnostic\",\"datePublished\":\"2026-03-10T13:12:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\\\/\"},\"wordCount\":1172,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260310050054r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\\\/\",\"name\":\"bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath\u00ae Lung Cancer Diagnostic - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260310050054r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-03-10T13:12:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260310050054r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260310050054r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath\u00ae Lung Cancer Diagnostic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath\u00ae Lung Cancer Diagnostic - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\/","og_locale":"en_US","og_type":"article","og_title":"bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath\u00ae Lung Cancer Diagnostic - Market Newsdesk","og_description":"bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath\u00ae Lung Cancer Diagnostic Study to evaluate clinical performance of CyPath\u00ae Lung for the early detection of lung cancer in high-risk patients Murtha Cancer Center Research Program at Uniformed Services University of the Health Sciences provides support for longitudinal study SAN ANTONIO&#8211;(BUSINESS WIRE)&#8211;bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company focused on non-invasive diagnostics and early cancer detection, today announced initiation of the Company\u2019s planned large-scale, longitudinal clinical study for CyPath\u00ae Lung, its noninvasive diagnostic test for the detection of early-stage lung cancer. The 2,000-patient longitudinal study is designed to evaluate the clinical performance of the CyPath\u00ae Lung flow cytometry test as a noninvasive diagnostic that uses sputum &hellip; Continue reading \"bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath\u00ae Lung Cancer Diagnostic\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-10T13:12:24+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260310050054r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath\u00ae Lung Cancer Diagnostic","datePublished":"2026-03-10T13:12:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\/"},"wordCount":1172,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260310050054r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\/","name":"bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath\u00ae Lung Cancer Diagnostic - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260310050054r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-03-10T13:12:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260310050054r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260310050054r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinal-clinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath\u00ae Lung Cancer Diagnostic"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/943135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=943135"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/943135\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=943135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=943135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=943135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}